Biotech stocks have proved to be an incredible wealth generator for long-term investors. In the prior decade, for instance, the iShares Nasdaq Biotechnology ETF (NASDAQ: IBB) nearly doubled the performance of the S&P 500. What's more, biotech equities may perform even better over the coming decade, thanks to the steady progress in key fields such as gene editing, gene therapy, and precision medicine. The biopharmaceutical industry, in fact, could make major strides over the next 10 years toward treating a range of diseases that currently have no standard of care.
Which biotech companies are set to lead the way in 2020? BioMarin Pharmaceutical (NASDAQ: BMRN), CRISPR Therapeutics (NASDAQ: CRSP), and Novavax (NASDAQ: NVAX) are three top biotech stocks that might be worth owning this year. Here's a brief overview for each company.
Image Source: Getty Images.
Source Fool.com